MedInfo World

Empowering patients through shared knowledge and community-driven health insights.

Platform

Drug Information
Health Conditions
Active Ingredients

Support

Help Center
Terms of Use
Privacy Policy
Disclaimer

Company

About Us
Contact

Medical Disclaimer

The information on this website is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Terms Privacy Disclaimer

Fasenra – Uses, Dosage, Side Effects & Warnings | MedInfo World | MedInfo World

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.

Home DrugsFasenra

Fasenra

Benralizumab

BenralizumabInterleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]3 Variants

Clinical Data

Brand Name

Fasenra

Generic Name

Benralizumab

Active Ingredient

Benralizumab

Drug Classes

Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

Important Notice

This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Fasenra, you must consult a qualified healthcare professional.

Available Variants (3)

Different strengths and dosage forms

Strength	Form	Route	NDC
10 mg/.5mL	INJECTION, SOLUTION	SUBCUTANEOUS	0310-1745
30 mg/mL	INJECTION, SOLUTION	SUBCUTANEOUS	0310-1730
30 mg/mL	INJECTION, SOLUTION	SUBCUTANEOUS	0310-1830